A recent study has revealed that a daily pill, known as amycretin, can lead to faster weight loss compared to existing injectable medications like Wegovy. Early trials demonstrated that patients taking amycretin lost an average of 13% of their body weight within 12 weeks, significantly outperforming the 6% weight loss seen in those receiving the Wegovy injection.
Key Findings
Developed by Novo Nordisk, the pharmaceutical company behind Ozempic and Wegovy, the pill works by mimicking the action of two peptide hormones that regulate hunger and blood sugar levels. This mechanism is similar to that of semaglutide and tirzepatide, the active ingredients in Ozempic and Wegovy, as well as Mounjaro.
In the initial trials, participants were given varying doses of amycretin, which were gradually increased. Those on a 50mg dose typically experienced a 10.4% reduction in body weight over the 12-week treatment period. Participants taking the maximum daily dose of two 50mg tablets lost an average of 13.1%. In contrast, those given a placebo reported an average weight loss of only 1.1%.
Implications for Obesity Treatment
The study’s authors concluded that a single molecule targeting both amylin and GLP-1 biology in pill form could provide a more convenient solution for individuals struggling with overweight and obesity. Importantly, the weight loss had not plateaued by the end of the 12-week trial, indicating the potential for further weight reduction with continued use.
However, experts emphasize that larger and longer-term studies are necessary to fully evaluate the drug’s safety profile and overall effectiveness.
Future Research and Considerations
Further large-scale trials are planned, with hopes that amycretin could become available within the next two years. Side effects reported in the study were consistent with those of other weight loss medications, including nausea, vomiting, and gastrointestinal issues.
Naveed Sattar, a Professor of Cardiomental Medicine at the University of Glasgow, commented on the significance of this early research: “The speed of weight loss seen in this new oral combination is exciting. However, much larger trials will be necessary to evaluate the long-term effects of these medicines on health outcomes.”
Conclusion
The development of amycretin represents a promising advancement in the fight against obesity. With its potential for quicker and more convenient weight loss, it could soon become a key player in the next generation of anti-obesity medications. As research continues, the medical community remains optimistic about its implications for effective weight management.
Related Topic:
Which Pills Make You Gain Weight
